Metabasis Therapeutics (MBRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Metabasis Therapeutics (MBRX)

MBRX 0.451

-4.8%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (41)	5/4/2007 4:37:48 PM
From: DewDiligence_on_SI	Read Replies (1) of 66

I’ve been watching Clevudine closely. It is IMO much more of a threat to Tyzeka and Baraclude than Pradefovir ever was. Regards, Dew p.s. CAGR’s are mathematically meaningless when you are starting from near zero; hence, your comment about the Tyzeka CAGR needed to reach $500M was silly.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next